Back to Directory
research logo

Phathom Pharmaceuticals | Company Profile

11/13/2025

Contact Information

👤
Phathom Pharmaceuticals
🏢
Phathom Pharmaceuticals
📍
100 Campus Drive, Suite 102, Florham Park, New Jersey 07932, US

Industry & Market

Primary Industry
research
All Industries
researchbiotechnology
Location
Florham Park, New Jersey, United States
Public Trading
NASDAQ: PHAT

Company Metrics

👥Total Employees
304
⚙️Engineering
1
💼Sales Team
251
📈Marketing
4
📅Founded
2018
💰Revenue
55.3M

Funding Information

Market Cap
$944.3M
Annual Revenue
$55,252,000
Publicly traded company

Headcount Distribution

Total Employees
304
Departments
19

By Department

Department Breakdown

Sales
Operations
Accounting
Business Development
Finance
Human Resources
Others

Technology Stack

Analytics & Tracking

Google AnalyticsGoogle Tag Manager

Social & Marketing

Google Dynamic RemarketingLinkedin Marketing Solutions

Development

Bootstrap Framework

Video & Media

Vimeo

Email & Communication

Outlook
Total: 28 technologies

Keywords & Focus Areas

biotechnologypharmaceuticalsrdcommercializationgastrointestinalgiinnovationdrug developmentbiotechnology: pharmaceutical preparationshealth carebiotechnology researchtherapeutic pipelinebiopharmagastric acid suppressionlate-stage developmentdrug efficacymedical devicespotassium-competitive acid blockerpharmacology+10 more
30 total keywords

Phathom Pharmaceuticals

Overview

Phathom Pharmaceuticals is a late clinical-stage biopharmaceutical company based in Florham Park, New Jersey. Dedicated to developing and commercializing innovative treatments for acid-related gastrointestinal disorders, the company focuses on therapies that target gastric acid secretion.

The lead product candidate, vonoprazan, is an oral small-molecule potassium-competitive acid blocker (P-CAB) currently in late-stage clinical development. With the potential to be the first gastric anti-secretory agent from a new drug class approved in North America or Europe in over 30 years, vonoprazan is also being investigated in combination with antibiotics for treating Helicobacter pylori infections. The company holds exclusive rights to vonoprazan in the US, Canada, and Europe, aiming to offer more effective therapeutic options and improve outcomes for patients with acid-related GI diseases.

Basic Information

Industry research
Founded 2018
Revenue 55.3M
Headquarters 100 Campus Drive, Suite 102, Florham Park, New Jersey 07932, United States
Alexa Ranking

Contact Details

Key Focus Areas & Initiatives

  • Biotechnology research and development
  • Innovative gastrointestinal therapeutics
  • Development and commercialization of acid suppression therapies
  • Late-stage clinical programs for gastric acid-related disorders
  • Potassium-competitive acid blocker (vonoprazan) innovation
  • Treatment strategies for Helicobacter pylori infections
  • Improving patient outcomes with novel therapies
  • Regulatory submissions for new drug approvals
  • Gastroenterology innovation and patient support

Technologies Used

  • AI
  • Amazon SES
  • Bootstrap Framework
  • DoubleClick
  • DoubleClick Conversion
  • Google Analytics
  • Google Cloud Hosting
  • Google Dynamic Remarketing
  • Google Font API
  • Google Tag Manager
  • Gravity Forms
  • Linkedin Marketing Solutions
  • Mimecast
  • Mobile Friendly
  • NetSuite
  • New Relic
  • Nginx
  • Outlook
  • Remote
  • Render
  • Salesforce
  • SparkPost
  • Twitter Advertising
  • Typekit
  • Vimeo
  • WP Engine
  • WordPress.org
  • reCAPTCHA

Affiliated Organizations & Regional Branches

    Need more information?

    Find decision makers, more insights and contact information about this company on Bitscale

    Start For Free

    Schedule your demo now!

    See how BitScale can supercharge your outbound sales in a 30-minute demo

    Start for Free

    Resources

    Careers

    Pricing

    homeCommunity

    Security

    SayData

    © 2026 Bitscale. Featherflow Technology Pvt Ltd.

    LinkedInTwitterInstagramYouTube
    AICPAGDPR
    CCPAISO
    LinkedInTwitterInstagramYouTube